Prospective, Multi-Center, Open-Label, Non-Randomized, Multi-Arm Study to Evaluate the Safety, Efficacy, and Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Implanted With a Posterior Chamber Intraocular Lens (PC-IOL) and Diagnosed With Mild to Moderate Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension. The main question it aims to answer is:
Does the BIM-DRS lower the pressure inside the eye to treat glaucoma or ocular hypertension?
Researchers will compare two different doses of the BIM-DRS implanted either with a pre-existing commercially available monofocal intraocular lens (IOL) or concurrently with the SpyGlass IOL (IOL with silicone pads (no drug)).
Participants will:
* Upon providing informed consent and successfully completing the screening visit, stop taking their IOP lowering medications in the eye to be treated.
* Complete a baseline visit to further evaluate eligibility in the study eye.
* Undergo surgery to implant the BIM-DRS (BIM-DRS and SpyGlass IOL for Cohorts 3 and 4). Only one eye of each participant will be treated.
* Complete post-operative follow-up visits for evaluation at Day 1, Week 2, Week 6, Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 (last study visit).

Start Date31 Jul 2026

Sponsor / Collaborator

SpyGlass Pharma, Inc.

NCT07217678

/ RecruitingPhase 4IIT

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Start Date09 Feb 2026

Sponsor / Collaborator

University of Miami

[+1]

NCT07218796

/ RecruitingPhase 3

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Start Date28 Oct 2025

Sponsor / Collaborator

SpyGlass Pharma, Inc.

100 Clinical Results associated with Bimatoprost

100 Translational Medicine associated with Bimatoprost

100 Patents (Medical) associated with Bimatoprost

983

Literatures (Medical) associated with Bimatoprost

29 Apr 2026·Nature Communications

Polyketal-conjugated tafluprost microparticles enable long-acting glaucoma therapy.

Article

Author: Mu, Jingqing ; Guo, Shutao ; Wang, Hanzhang ; Gordon, Akiva ; Guo, Shuang-Zhuang ; Nakagawa, Yoshiyuki ; Wang, Weiping ; Zhong, Haiping ; Wei, Tuo ; Zhou, Xueyan ; Yuan, Xiaoyong ; Yu, Na ; Zhan, Changyou ; Barhoumi, Aoune ; Santamaria, Claudia ; Kohane, Daniel S

Long-acting formulations are increasingly sought after for the management of chronic diseases. Drug-conjugated microparticles with degradation-controlled release present a promising modular extended-release platform that can be delivered through minimally invasive approaches. However, many conventional drug-conjugated microparticles have relatively short durations of release and substantial release of pharmacologically inactive drug-conjugated oligomers. Here, we present surface-erodible, drug-conjugated polyketal microparticles for extended release of unmodified pharmacologically active drug. Microparticles made of a polyketal conjugated to the anti-glaucoma agent tafluprost initially release unmodified tafluprost, then about two weeks later predominantly release the biologically active tafluprost acid due to the mildly base-catalyzed hydrolysis of tafluprost, with a cumulative total drug release of ~78% over 540 days in vitro. Notably, no detectable drug-conjugated oligomers are found in release medium. Tafluprost-polyketal conjugate microparticles that further encapsulate unconjugated tafluprost reduce intraocular pressure for approximately 3 months after subconjunctival injection in ocular normotensive female rats, exhibiting a low grade of tissue reaction, no retinal abnormalities or systemic side effects, and enhanced intraocular pressure-lowering efficacy compared with a long-acting bimatoprost-loaded biodegradable implant in an ocular hypertensive rat model. Our findings have broad implications in advancing extended drug delivery systems.

01 Apr 2026·BRITISH JOURNAL OF OPHTHALMOLOGY

Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study

Article

Author: Oddone, Francesco ; Gościniewicz, Piotr ; Cordeiro, M Francesca ; Rokicki, Dariusz MD ; Stalmans, Ingeborg ; Nisslé, Sylvie ; Mermeklieva, Elena Atanasova

Background/Aims:

To compare the efficacy and safety of a new preservative-free bimatoprost 0.01%/timolol 0.1% fixed combination (BTFC) eye gel with those of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (BTFC eye drops) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Methods:

In this phase III, international, multi-centre, randomised, parallel group, investigator-masked study, patients receiving a first-line monotherapy, having insufficiently controlled intraocular pressure (IOP) and requiring dual therapy were randomised to receive either BTFC eye gel or BTFC eye drops once daily for 12 weeks. The primary efficacy endpoint was the change in IOP from baseline to week 12 at 08:00 in the assessed eye. Further efficacy and safety endpoints were assessed as secondary outcomes.

Results:

The mean±SD change in IOP from baseline to week 12 at 08:00 was −10.96±3.43 mmHg for the BTFC eye gel group and −11.14±3.56 mmHg for the BTFC eye drop group. The least-squares mean difference (BTFC eye gel minus BTFC eye drops) was −0.04±0.24 mmHg (95% CI −0.51 to 0.43 mmHg), with the upper bound of the 95% CI lower than the predefined margin of +1.5 mmHg at week 12 at 08:00. Similar IOP-lowering efficacy was demonstrated at all other timepoints. The safety profile was comparable between the treatment groups. No patients in the BTFC eye gel group discontinued the study due to a treatment-related adverse event compared with 8 (2.9%) patients in the BTFC eye drop group.

Conclusion:

Low-concentration BTFC eye gel can be considered as a safe and effective treatment in the therapeutic management of glaucoma and OHT.

04 Mar 2026·Cureus Journal of Medical Science

Use of Bimatoprost Intracameral Implant for the Treatment of Glaucoma: A Focused Narrative Review

Review

Author: Rizwan Khan, Arham Yahya

The objective of this focused narrative review is to summarize clinical and preclinical evidence on intracameral bimatoprost implants for adults with open-angle glaucoma (OAG) or ocular hypertension (OHT), focusing on comparative efficacy, safety, and adherence-related outcomes. PubMed/MEDLINE and Google Scholar were searched from inception through January 31, 2026, using combinations of the terms bimatoprost implant, bimatoprost sustained-release, bimatoprost SR, Durysta, glaucoma, and ocular hypertension. Eligible reports included human clinical trials or observational studies evaluating any intracameral bimatoprost implant dose in OAG or OHT, and relevant nonclinical pharmacokinetic or pharmacodynamic studies. Conference abstracts without full text and non-English reports were excluded. Records were screened at the title/abstract level followed by full-text review, and data were extracted on intraocular pressure change, need for rescue therapy or additional procedures, treatment-emergent adverse events (TEAEs), and corneal endothelial cell density (CECD). Across phase I/II and phase III trials, bimatoprost implants produced intraocular pressure reductions comparable to topical timolol or topical bimatoprost through early follow-up, and many eyes remained drop-free for months to a year. Corneal adverse events and CECD loss were infrequent after single administration but increased with fixed-interval repeat dosing, with a less favorable profile at higher dose strengths. It was concluded that intracameral bimatoprost implants offer a drop-sparing alternative that may reduce adherence burden, but careful patient selection and monitoring for corneal endothelial effects are central to safe use.

150

News (Medical) associated with Bimatoprost

08 Jun 2026

·www.globenewswire.com

Reminder: Nicox June 2024 Warrants will expire June 19, 2026

Press Release Reminder: Nicox June 2024 Warrants will expire June 19, 2026June 8, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today reminds holders of the warrants issued in June 2024 as part of the Company’s equity offering with preemptive rights that these warrants will expire on Friday, June 19, 2026, close of market day, after which date they will have no value. The last possible date for trading the warrants will be Tuesday, June 16, 2026, close of market day, after which time they will be delisted.The June 2024 warrants are only held by investors who participated in the June 2024 financing, or who bought the warrants on Euronext Growth Paris. Reminder of the main features of the warrants Listing of the warrants: The warrants are listed on Euronext Growth ParisISIN code: FR001400QEQ3Exercise period: from June 21, 2024 to June 19, 2026 (close of market)Exercise parity: 5 warrants give the holder the right to subscribe to 2 new Nicox sharesExercise price: The warrant holder pays €0.275 per new share Any warrants not exercised by the close of market day on Friday, June 19, 2026 will automatically expire, will no longer be exercisable and will no longer have any value. Shares issued via exercise of the warrants are traded as identical to existing Nicox shares.Exercise procedureTo exercise their warrants, holders should contact the financial intermediary holding their securities account (bank or broker). The Company is not in a position to advise holders as to whether they hold warrants nor to accept any exercise or trading instructions. Details of the warrants from the June 2024 financing are given in the Q&A section of our website: www.nicox.com.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.comDisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2025” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_WarrantsReminderJune2026_FINAL

Drug Approval

02 Jun 2026

·www.biospace.com

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing. Mr. Pinder brings over 20 years of commercial launch experience in ophthalmology, focused on building, launching, and evolving significant brands, notably in the buy-and-bill specialty pharma model. At SpyGlass Pharma, he will build and lead the marketing function for the company as it continues to progress the Bimatoprost Drug Pad-IOL System (BIM-IOL System) through Phase 3 clinical trials and towards potential commercialization upon FDA approval. “We are thrilled to welcome Mike to SpyGlass Pharma as we continue to enroll participants into our two BIM-IOL System Phase 3 trials,” said Patrick Mooney, chief executive officer of SpyGlass Pharma. “Mike’s deep experience in building successful ophthalmology brands across buy-and-bill specialty pharma and medical device products will augment our plans for a successful BIM-IOL launch.” Mr. Pinder has a proven track record of building and launching significant ophthalmology brands with award-winning campaigns. He was most recently head of IZERVAY ® marketing at Astellas Pharma, which under his brand leadership delivered significant growth. Prior to launching IZERVAY ® , Mike led patient marketing in the Novartis ophthalmology buy-and-bill retina franchise and hospital marketing at Johnson & Johnson, cultivating ophthalmology marketing launch experiences across a range of brands. Prior to these roles, Mr. Pinder held positions in payer marketing and sales leadership at Johnson & Johnson. He holds a Bachelor of Arts Degree in communications from the University of Massachusetts Amherst. “I am thrilled to join SpyGlass Pharma and help advance the company’s mission to give patients vision that endures with drug delivery that lasts,” said Mr. Pinder. “The BIM-IOL System is a first-and-only product: the 2-for-1 vision solution and the glaucoma sustained drug delivery option that every single cataract surgeon can do. I look forward to the potential of bringing this technology to a community desperately in need of more drop-free alternatives to glaucoma management.” About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine. Forward-looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding: the potential benefits and impact of the BIM-IOL System on patients, anticipated presentation of additional data, and SpyGlass Pharma’s plans relating to the clinical development of the BIM-IOL System towards commercial launch after FDA approval. The forward-looking statements contained herein are based upon SpyGlass Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in the Risk Factors section of the company’s Quarterly Report on Form 10-Q for the three month period ended March 31, 2026 filed with the Securities and Exchange Commission on May 14, 2026, and in similar disclosures set forth in the other documents that SpyGlass Pharma may time to time with the SEC. These forward-looking statements are made as of the date of this press release, and SpyGlass Pharma assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Media Contact: Nami Surendranath (402) 507-6757 nsurendranath@dnacommunications.com Investor Contact: Ami Bavishi or Nick Colangelo Gilmartin Group LLC investors@spyglasspharma.com

Executive ChangePhase 3

21 May 2026

·www.globenewswire.com

SpyGlass Pharma to Participate in Upcoming Investor Conferences

ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology ForumDate: Tuesday, May 26, 2026Time: 2:00 p.m. ETFormat: Fireside Chat Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 2:35 p.m. ETFormat: Fireside Chat Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Time: 10:40 a.m. ETFormat: Corporate Presentation A live webcast and subsequent replay of each presentation can be accessed via the Investor Relations section of the Company website at www.spyglasspharma.com. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine. Media Contact:Nami Surendranath+1 (402) 507-6757nsurendranath@dnacommunications.com Investor Contact:Ami Bavishi or Nick ColangeloGilmartin Group LLCinvestors@spyglasspharma.com

100 Deals associated with Bimatoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D02724	Bimatoprost	S01EE03	DB00905

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Takeda Pharmaceutical Co., Ltd.	07 Jul 2009
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	07 Jul 2009
Hypotrichosis	United States	AbbVie, Inc.	24 Dec 2008
Glaucoma, Open-Angle	United States	AbbVie, Inc.	16 Mar 2001
Ocular Hypertension	United States	AbbVie, Inc.	16 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cataract	Phase 3	United States	SpyGlass Pharma, Inc.	15 Oct 2025
Hydrophthalmos	Phase 3	United States	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	France	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Italy	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Philippines	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	South Korea	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Taiwan Province	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	United Kingdom	Allergan UC	01 Sep 2011
Alopecia	Phase 3	Japan	Allergan UC	01 Jul 2011
Androgenetic Alopecia	Phase 2	United States	Allergan UC	01 Jun 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06120842 (Tigris, GlobeNewswire) Manual	Phase 1/2	Ocular Hypertension	-	Bimatoprost	lcjcgbutgn(zdtowimyuv) = pqfkszipzs brvhxrzaws (txitkrtlsh ) View more	Positive	14 Oct 2025
FDA_CDER Manual	Not Applicable	Glaucoma, Open-Angle \| Ocular Hypertension	-	0.01% ZOLYMBUS	lbojmdicxx(ohzvpdradu) = OLYMBUS once daily (in the evening) was non-inferior to preserved bimatoprost ophthalmic solution 0.01%. ktcbgwjtuq (eyoudkctvu ) View more	Positive	09 Sep 2025
				0.01% preserved bimatoprost ophthalmic solution
NCT03891446 (MAIA, ARVO2025)	Phase 3	Glaucoma, Open-Angle \| Ocular Hypertension	75	1 administration of 10 μg Intracameral Bimatoprost	praohtvfhw(xrruhauwog) = xqsbshwnch ligpdyuzfx (xmhvwxydsn, 1.23)	Positive	04 May 2025
				2 administrations of 10 μg Intracameral Bimatoprost	praohtvfhw(xrruhauwog) = nkvyivsokv ligpdyuzfx (xmhvwxydsn, 1.45)
NCT03850782 (TRITON, Pubmed \| Drugs)	Phase 3	Ocular Hypotension	441	Bimatoprost implant 10 µg	nwmpprbnfl(hopadtijec) = hxujbeuozb mroafcwrlb (ukuczofsuu, 369 - 485) View more	Positive	01 Apr 2025
NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	LL-BMT1LL-BMT1 32-µg dose	fmaoiglalh(xoyjkeidud) = nekjhggzqg jfozxlsuar (mjzytmrojd ) View more	Positive	12 Nov 2024
				bimatoprostbimatoprost 0.01%	-
NCT02507687 (CTgov)	Phase 3	Glaucoma, Open-Angle	240	SLT (Stage 2: SLT)	gmlitqhell(xyhhdhjnpu) = akdagituow bwqzxsafsn (avgpbyoltb, 0.28) View more	-	10 May 2024
				Bimatoprost SR (Stage 2: Bimatoprost SR 10 µg)	gmlitqhell(xyhhdhjnpu) = cmlsvcmgvx bwqzxsafsn (avgpbyoltb, 0.28) View more
NCT03850782 (ARVO2024)	Phase 3	Glaucoma, Open-Angle \| Ocular Hypertension	423	Bimatoprost implant (Open-angle glaucoma or Ocular hypertension)	mpmblktmqu(nhewmelxoj) = wghheltjgz rggqwcqicy (kjuinwuamz ) View more	Positive	05 May 2024
ARVO2024	Not Applicable	Ocular Hypertension \| Glaucoma, Open-Angle	792	Bimatoprost SR implant	ylewnpbzuu(ipxezpnqko) = mzefbmzlvr bbarspeajq (mhodzhsysr )	Positive	05 May 2024
NCT03825380 (CTgov)	Phase 3	Glaucoma, Open-Angle \| Glaucoma	485	Bimatoprost (T4032)	kfqffrxqsv(xccxzwvoik) = hxhnqpxdxa jraiqfdkzh (lrxcqtpxbl, 0.19) View more	-	21 Nov 2023
				Lumigan® (Lumigan®)	kfqffrxqsv(xccxzwvoik) = jgsjdpoxot jraiqfdkzh (lrxcqtpxbl, 0.18) View more
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	Bimatoprost SR (Bimatoprost SR 10 μg)	pklujybnlz(hrujmuoxgq) = okdnnrdqth qxnksfnziy (eecogrwcux, 5.65) View more	-	08 Jun 2023
				LUMIGAN (LUMIGAN 0.01%)	pklujybnlz(hrujmuoxgq) = mzdecpyfex qxnksfnziy (eecogrwcux, 5.27) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis